Inês Martins, PhD, managing science editor —

The nonprofit Claire’s Place Foundation has launched a pilot program to help 15 adults with cystic fibrosis (CF) or caregivers of patients acquire flexible employment, enabling them to continue working while dealing with the disease’s daily needs. The Work Proudly Program aids people in choosing careers and gaining the…

A Phase 1/2 clinical trial assessing Arrowhead Pharmaceuticals‘ investigational inhaled therapy, ARO-ENaC, for the treatment of cystic fibrosis (CF), has dosed its first participants, the company announced. The AROENaC1001 trial (NCT04375514) is designed to investigate ARO-ENaC in 24 healthy volunteers and 30 CF patients, and is…

The Cystic Fibrosis Foundation has committed $20 million to support the development of innovative therapeutics and early-stage companies focusing on cystic fibrosis (CF). In collaboration with venture capital firm Longwood Fund, the funding is part of the foundation’s Path to a Cure, a $500 million initiative…

A national newborn screening (NBS) program in the Republic of Ireland suggests that the incidence of cystic fibrosis and CF carriers in the country is lower than previously estimated, a study found. It also shows that the Gly551Asp mutation is almost three times more common among newborns in Ireland…

ContraFect has been awarded to $18.9 million by the nonprofit investment group CARB-X to advance CF-370 as a potential treatment for Pseudomonas aeruginosa infections. These bacteria and the thick layer of biofilm they produce are a major cause of pulmonary exacerbations in cystic fibrosis (CF) patients. CARB-X, which stands for…

AR-501, an inhaled treatment candidate for chronic lung infections in people with cystic fibrosis (CF), has been deemed safe and well-tolerated in healthy volunteers, results from the first part of a Phase 1/2a clinical trial show. The trial’s safety monitoring committee (SMC) and a data safety monitoring board…

A combination of two mutations, including one that had never been reported, were found in two Chinese siblings who developed a severe form of cystic fibrosis (CF), according to a case report. The report, “Identification of a Mutation in the Novel Compound Heterozygous CFTR in a…

Microbion has been awarded up to $17.1 million from the nonprofit CARB-X and the Cystic Fibrosis Foundation to complete preclinical and Phase 1 clinical studies of its inhaled antimicrobial medication pravibismane for treating cystic fibrosis (CF) patients with lung infections. CARB-X — Combating Antibiotic-Resistant Bacteria…

In addition to restoring CFTR protein function in cells, the cystic fibrosis (CF) therapies Orkambi (lumacaftor/ivacaftor) and Symdeko (tezacaftor/ivacaftor combo) significantly reduce the excessive inflammation that damages patients’ lungs, a recent study suggests. Symdeko seems to be more potent than Orkambi at dampening inflammatory responses.

Oxford Hospitals Charity has purchased and delivered machines able to measure lung function at home to 120 young patients with cystic fibrosis (CF) in the U.K., enabling them to closely monitor their condition during the COVID-19 pandemic. The mini lung function machines were funded with the…